SINUS-52

DUPIXENT 300 mg Q2W + INCS significantly decreased sinus opacification vs placebo + INCS, as measured by LMK-CT at Week 24 (key secondary endpoint), with sustained improvement through Week 52 (other secondary endpoint) in SINUS-52.⁴

Week 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -5.13 (95% CI: -5.80, -4.46) (-5.21 from a baseline score of 18.12 vs -0.09 from a baseline score of 17.65, respectively) (P<0.0001).⁴

Week 52 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -6.94 (95% CI: -7.87, -6.01) (-6.83 from a baseline score of 18.42 vs 0.11 from a baseline score of 17.65, respectively).⁴

Analysis of change at Week 52 was not multiplicity controlled; result is descriptive.⁴

Lund-Mackay computed tomography (LMK-CT) score (range 0-24): reduced score indicates improvement.¹

INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

See the full data on sinus opacification